RxDoctor Payments Data

John Messenger, MD

Interventional Cardiology · Aurora, CONPI 1770673451

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,286 of the $9,485 with a category attached, or 76.8%. 13 manufacturers reported payments, led by Edwards Lifesciences at 42.1% of the total. 2025 is the largest year on record at $2,094, 2.4 times the $882 reported in 2019.

$9,485in general payments, 2019–2025

Across 155 payments — averaging $61.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$4K
  • Medtronic$2K
  • Ancora Heart, Inc.$738
  • Heartflow, Inc.$664
  • Abbott$444
  • Philips North America LLC$348
  • plus $825 from 7 others
$165,766in research payments, 2019–2025

Across 32 payments — averaging $5180.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$102K
  • Philips North America LLC$64K

What the payments were for

  • Travel & lodging$2,17323%
  • Food & beverage$7,28677%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,485 in reported general payments places this provider in the 55th percentile of 111 interventional cardiology providers in Colorado.

See all interventional cardiology providers in Colorado

Medicare billing

Part B allowed, 2024
$112,650
Medicare patients
371
Services billed
761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab96$67,301
XareltoRivaroxaban15$23,345
Praluent PenAlirocumab23$16,552
BrilintaTicagrelor14$13,560
EntrestoSacubitril/Valsartan13$11,293
Rosuvastatin Calcium107$1,474
Atorvastatin Calcium106$1,281
Ezetimibe16$833
Metoprolol Succinate60$629
ClopidogrelClopidogrel Bisulfate23$519
Amlodipine Besylate25$206
Metoprolol Tartrate38$204
Losartan Potassium42$198
Lisinopril27$174
Spironolactone13$116

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →